AOP Orphan is a European pioneer in the development, production and marketing of treatments for people with rare diseases also known as orphan diseases.
"I am very proud to work for AOP Orphan Pharmaceuticals GmbH and lead the German team. The company has been investing for decades in the medicines and medical devices for the treatment of patients with rare diseases, such as myeloproliferative disorders (MPN). Our focus is to help every single patient in Germany."
AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the German health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Germany occupies a particular position among many countries where AOP Orphan is represented since it was one of the first expansion territory. The company began its development in Germany in 2011 and was transformed into a legal entity in 2018.
AOP Orphan Germany is a team of around eight employees in the Marketing & Sales, Medical Affairs and Market Access in HematoOncology division.